Coultreon banks $125M to support testing of former Galapagos immune drug
BioPharma Dive
Backed by Novo Holdings, Regeneron s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.
pharminent
April 28, 2026 (Last updated: April 29, 2026)
BioPharma Dive
Backed by Novo Holdings, Regeneron s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating many immunological diseases.
